Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 14Completed 9Withdrawn 5Active not recruiting 3No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Lymphoid 1

Conditions

Unresectable Colorectal Cancer 1Pancreatic Neoplasms 1Hodgkin Disease 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × magrolimab × Clear all
NCT04788043 2025-04-02

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Stanford University

Phase 2 Active not recruiting
8 enrolled
Lymphoid

Hodgkin Disease

NCT06532344 2024-11-14

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Ono Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
32 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06540261 2024-09-19

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Ono Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
65 enrolled
Gastrointestinal

Unresectable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡